Neoleukin Therapeutics EBIT

Neoleukin Therapeutics posts a EBIT of $-110M as of March 2026. That compares with $-120M in the prior-year period — up 9.6% year over year. That is below the Healthcare sector average of $22B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Neoleukin Therapeutics's EBIT was $-120M. The latest reading is $-110M — a 9.6% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $22B is typical. Neoleukin Therapeutics's $-110M is lower that level. That is roughly 100.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Neoleukin Therapeutics's financial statement story. At $-110M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NLTX's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $22B), and (3) consistency with growth and profitability. This page covers the first two; Neoleukin Therapeutics's other metric pages and overview cover the third.